Antifungal Antagonism Screening

抗真菌拮抗剂筛选

• 批准号: 10919697
• 负责人: Alexey Zakharov
• 金额: $ 24.08万
• 依托单位: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10919697
• 关键词: Amphotericin B; Antifungal Agents; Antifungal Therapy; Aspergillus fumigatus; Automobile Driving; Azoles; Basic Science; Biological Assay; Candida albicans; Cryptococcus neoformans; Fungal Drug Resistance; Health; Human; Human Genome; Mycoses; National Center for Advancing Translational Sciences; Patients; Pharmaceutical Preparations; Predisposition; Rare Diseases; Reporting; Research; Translations; Work; antagonist; clinical efficacy; drug candidate; high throughput screening; improved; mortality; pathogenic fungus; pharmacologic; programs; resistance mechanism; screening; tool

The NCATS Early Translation Branch (ETB) hosts a broad and comprehensive program for the discovery of drug candidates directed towards rare diseases and pharmacological tools to probe the function of the human genome. ETB conducts research to understand the underlying principles driving the translation of basic research discoveries into tangible improvements in human health. During the reporting period, the collaborative team worked to develop a high-throughput screening assay to identify compounds that reduce the susceptibility of four major human fungal pathogens (C. albicans, C. glabrata, C. neoformans and A. fumigatus) to the most commonly used classes of antifungal drugs (azoles, amphotericin B and echinocandins). This will identify a list of medications that may undermine the clinical efficacy of currently used antifungal drugs.

NCAT的早期翻译分支（ETB）举办了一个广泛而全面的计划，用于发现针对罕见疾病和药理工具的候选药物，以探测人类基因组功能。 ETB进行研究，以了解将基础研究发现转化为人类健康的切实改善的基本原则。 在报告期间，合作团队致力于开发高通量筛查测定法，以识别降低四种主要人类真菌病原体（C. blabrata，C。glabrata，C。neoformans和A. fumigatus）对最常用的抗真菌药物（Azoles，Azoles，Amphotericercin B和Achechiencand）的易感性。这将确定可能破坏当前使用抗真菌药物的临床功效的药物清单。